The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Dextroamphetamine for Cocaine-Dependence Treatment: A Double-Blind Randomized Clinical Trial
Abstract
A properly implemented agonist treatment regimen should improve retention and reduce illicit drug use. Cocaine-dependent subjects (N = 128) were enrolled in a 12-week randomized, double-blind, placebo-controlled trial. In the multistage dosing design, subjects initially received placebo (PBO) or 15 to 30 mg of dextroamphetamine sulfate, sustained-release capsules. At week 5, the dose doubled to 30 mg or 60 mg for active groups. Subjects attended the clinic twice a week, provided urine samples, obtained medication, and had one behavioral therapy session a week. Retention was best for the 15- to 30-mg group, whereas the proportion of benzoylecgonine-positive urine screens was, from lowest to highest, 30 to 60 mg, 15 to 30 mg, and PBO at study end. Dosing must be refined. The results provide support for additional examination of the agonist model in psychostimulant-dependence treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among homeless and unstably housed women in San Francisco, 47% reported use of cocaine or methamphetamine in the past 6 months, and 14% of those who did not use stimulants at baseline initiated stimulant use within 6 months.231”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [231]
In the citing paper
“Dextroamphetamine causes release of DA (as well as norepinephrine and serotonin) and is an effective treatment for amphetamine abuse [181].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [181]
Citations
Cites
The Fifth Edition of the Addiction Severity Index.
Mclellan, A., Kushner, H., Metzger, D., Peters, R., Smith, I. E., Grissom, G. R., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,280
Desipramine Facilitation of Initial Cocaine Abstinence
Gawin, F. H. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810020019004 · Cited by 361
Replacement Medication for Cocaine Dependence
Grabowski, J. G., Roache, J. D., Schmitz, J. M., Rhoades, H. M., Creson, D. L., & Korszun, A. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199712000-00008 · Cited by 191
Self-citationGrabowski, J. G., Rhoades, H. M., Elk, R., Schmitz, J. M., Davis, C., Creson, D., & Kirby, K. C. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199506000-00004 · Cited by 155
Self-citationDesipramine Treatment of Cocaine Dependence in Methadone-Maintained Patients
Arndt, I. O. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110052008 · Cited by 139
Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency.
Rhoades, H. M., Creson, D. L., Elk, R., Schmitz, J. M., & Grabowski, J. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.1.34 · Cited by 129
Self-citationMethylphenidate Treatment of Cocaine Abusers without Attention Deficit Disorder: A Negative Report
Gawin, F. H., Riordan, C. E., & Kleber, H. D. (1985) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952998509016861 · Cited by 120
Methylphenidate (Ritalin®) treatment of cocaine dependence—A preliminary report
Khantzian, E. J., Gawin, F. H., Kleber, H. D., & Riordan, C. E. (1984) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(84)90033-3 · Cited by 120
Levin, F., & Kleber, H. (1995) · Harvard Review of Psychiatry · doi:10.3109/10673229509017144 · Cited by 114
Fluoxetine for Cocaine Dependence in Methadone
Batki, S. L., Manfredi, L., Jacob, P., & Jones, R. T. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199308000-00003 · Cited by 105
Reinforcing and subjective effects of methylphenidate in humans
Chait, L. D. (1994) · Behavioural Pharmacology · doi:10.1097/00008877-199406000-00005 · Cited by 69
Charnaud, B., & Griffiths, V. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00052-0 · Cited by 43
Effects of carbamazepine on acute responses to smoked cocaine-base in human cocaine users
Hatsukami, D., Keenan, R. M., Halikas, J. A., Pentel, P. R., & Brauer, L. H. (1991) · Psychopharmacology · doi:10.1007/bf02244565 · Cited by 39
Medication take-home doses and contingency management.
Schmitz, J. M., Rhoades, H. M., Elk, R., Creson, D. L., Hussein, I., & Grabowski, J. (1998) · Experimental and Clinical Psychopharmacology · doi:10.1037//1064-1297.6.2.162 · Cited by 38
Self-citationLaboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment.
Roache, J., Grabowski, J., Schmitz, J. M., Creson, D. L., & Rhoades, H. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200002000-00011 · Cited by 38
Self-citationMedication take-home doses and contingency management.
Schmitz, J. M., Rhoades, H. M., Elk, R., Creson, D. L., Hussein, I., & Grabowski, J. G. (1998) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.6.2.162 · Cited by 37
Self-citationBest, D. W., Gossop, M., Stewart, D., Marsden, J., Lehmann, P., & Strang, J. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00132-x · Cited by 27
A Review of Pharmacotherapie for Substance Abuse
Kosten, T. R., & McCance, E. F. (1996) · American Journal on Addictions · doi:10.3109/10550499608995657 · Cited by 26
Research Issues Related to Development of Medications for Treatment of Cocaine Addiction
Klein, M. B. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb08223.x · Cited by 25
Sofuoglu, M., Pentel, P. R., Bliss, R., Goldman, A. I., & Hatsukami, D. K. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00140-9 · Cited by 18
A Review of Pharmacotherapies for Substance Abuse
Kosten, T. R., & McCance, E. F. (1996) · American Journal on Addictions · doi:10.1111/j.1521-0391.1996.tb00479.x · Cited by 16
The Pharmacotherapy of Relapse Prevention Using Anticonvulsants
Kosten, T. R. (1998) · American Journal on Addictions · doi:10.1111/j.1521-0391.1998.tb00338.x · Cited by 7
Research works printed but not linked: 1
- Batki, 1992, J Clin Psychopharmacol, 13, 243
Cited by
Sorted by citations
Monoamine transporters and psychostimulant drugs.
Rothman, R., & Baumann, M. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.054 · Cited by 509
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299
“Dextroamphetamine causes release of DA (as well as norepinephrine and serotonin) and is an effective treatment for amphetamine abuse [181].”
BackgroundThe treatment of cocaine use disorder
Kampman, K. M. (2019) · Science Advances · doi:10.1126/sciadv.aax1532 · Cited by 250
The effectiveness of compulsory drug treatment: A systematic review
Werb, D., Kamarulzaman, A., Meacham, M. C., Rafful, C., Fischer, B., Strathdee, S. A., & Wood, E. (2016) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.12.005 · Cited by 260
Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence.
Grabowski, J., Shearer, J., Merrill, J., & Negus, S. (2004) · Addictive Behaviours · doi:10.1016/j.addbeh.2004.06.018 · Cited by 254
Self-citation
Metadata
- Authors
- Grabowski, J., Rhoades, H., Schmitz, J., Stotts, A., Daruzska, L. A., Creson, D., & Moeller, F. G.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2001-10
- Volume
- 21
- Issue
- 5
- Pages
- 522-526
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2052304909
- Cited by
- 243
- References
- 22
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 10 · 2023: 7 · 2022: 5 · 2021: 12 · 2020: 10 · 2019: 8 · 2018: 9 · 2017: 6 · 2016: 14 · 2015: 13 · 2014: 12 · 2013: 11 · 2012: 13
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p50da009262-20)
- National Institute on Drug Abuse (DA RO1-6143, DA P50-9262)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- d-amphetamine, cocaine dependence, treatment retention, illicit drug use, dose escalation, urine drug testing, benzoylecgonine, stimulant use disorder, behavior therapy
- MeSH terms
- Adult, Central Nervous System Stimulants, Behavior Therapy, Cocaine, Delayed-Action Preparations, Dextroamphetamine, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Patient Compliance, Patient Dropouts, Severity of Illness Index, Substance Abuse Detection, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
